A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity

Robert M. Conry, Albert F. LoBuglio, Frosty Loechel, Susan E. Moore, Lucretia A. Sumerel, Daunte L. Barlow, David T. Curiel

Research output: Contribution to journalArticlepeer-review

121 Scopus citations


We have constructed a plasmid DNA encoding the full-length cDNA for human carcinoembryonic antigen (CEA) driven by the cytomegalovirus early promoter/enhancer and demonstrated that this plasmid can function as a polynucleotide vaccine. The immune response elicited by the CEA polynucleotide vaccine is dose and schedule dependent. There appears to be a threshold dose of 50 μg capable of inducing CEA-specific lymphoblastic transformation, lymphokine release, and antibody response. Doses of 10 μg were significantly less effective. When 50-μg doses are employed, thrice weekly or weekly vaccination schedules more reliably elicit CEA-specific immune responses by day 43 than does an every-3-weeks schedule. Furthermore the CEA polynucleotide vaccine can immunoprotect against challenge with syngeneic CEA-transduced colon carcinoma cells as early as 3 weeks after the first vaccination. Studies are ongoing to demonstrate the ability of CEA polynucleotide vaccination to treat pre-existing syngeneic mouse colon and breast carcinomas expressing human CEA.

Original languageEnglish
Pages (from-to)59-65
Number of pages7
JournalGene therapy
Issue number1
StatePublished - Feb 3 1995


  • Cancer
  • Carcinoembryonic antigen
  • Gene therapy
  • Genetic immunization
  • Polynucleotide vaccine
  • Tumor


Dive into the research topics of 'A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity'. Together they form a unique fingerprint.

Cite this